<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646474</url>
  </required_header>
  <id_info>
    <org_study_id>201617027.2p</org_study_id>
    <nct_id>NCT03646474</nct_id>
  </id_info>
  <brief_title>Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC</brief_title>
  <official_title>Evaluation of the Efficacy &amp; Safety of a Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal
      saline over 20 minutes after induction of anesthesia and before surgical incision. In the
      control group, patients will receive a placebo of 100 mL 0.9% normal saline. The primary
      endpoint is reduction in blood loss, while the secondary endpoint was the number of patients
      needing transfusion and occurrence of postoperative thrombotic complications (myocardial
      infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days
      after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in blood loss</measure>
    <time_frame>1st 24 hours.</time_frame>
    <description>Blood loss will be calculated (volume estimated as the blood remaining in sponges and drapes and the volume in suction bottles during surgery).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Cytoreductive Surgery</condition>
  <arm_group>
    <arm_group_label>tranexamic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic Acid infusion</intervention_name>
    <description>The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.</description>
    <arm_group_label>tranexamic acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline infusion</intervention_name>
    <description>In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  ASA 1 and ASA 2 patients scheduled for colorectal cancer surgery.

          -  Age above 18 years &amp; less than 65 years.

        Exclusion criteria:

          -  Thrombophilia or any bleeding disorder.

          -  Previous or active thromboembolic disease.

          -  Family history of thromboembolism.

          -  Known Allergy to TA.

          -  Liver dysfunction.

          -  Preexisting renal dysfunction (serum creatinine &gt;1.2 mg/dL).

          -  Coronary stent insertion within a year prior to operation.

          -  Cardiovascular problem (e.g., myocardial infarction, atrial fibrillation, angina,
             heart failure),

          -  Lifelong warfarin therapy for thromboembolism prophylaxis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Othman</last_name>
    <phone>00201005098394</phone>
    <email>ahmadhothman@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekramy Mansour, MD</last_name>
      <phone>00201224642810</phone>
      <email>ekrameymansoure@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed H Othman</investigator_full_name>
    <investigator_title>Assisstant professor of Anesthesia ICU and pain Relief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

